INNV vs. LFST, PRVA, USPH, PNTG, WGS, TALK, DCGO, SHCR, PIII, and EUDA
Should you be buying InnovAge stock or one of its competitors? The main competitors of InnovAge include LifeStance Health Group (LFST), Privia Health Group (PRVA), U.S. Physical Therapy (USPH), The Pennant Group (PNTG), GeneDx (WGS), Talkspace (TALK), DocGo (DCGO), Sharecare (SHCR), P3 Health Partners (PIII), and EUDA Health (EUDA). These companies are all part of the "health services" industry.
InnovAge (NASDAQ:INNV) and LifeStance Health Group (NASDAQ:LFST) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, community ranking, institutional ownership, valuation, dividends and profitability.
InnovAge has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, LifeStance Health Group has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.
LifeStance Health Group received 10 more outperform votes than InnovAge when rated by MarketBeat users. Likewise, 26.32% of users gave LifeStance Health Group an outperform vote while only 0.00% of users gave InnovAge an outperform vote.
InnovAge has a net margin of -4.16% compared to LifeStance Health Group's net margin of -15.69%. InnovAge's return on equity of -10.51% beat LifeStance Health Group's return on equity.
12.3% of InnovAge shares are owned by institutional investors. Comparatively, 85.5% of LifeStance Health Group shares are owned by institutional investors. 0.4% of InnovAge shares are owned by insiders. Comparatively, 6.6% of LifeStance Health Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, LifeStance Health Group had 1 more articles in the media than InnovAge. MarketBeat recorded 5 mentions for LifeStance Health Group and 4 mentions for InnovAge. InnovAge's average media sentiment score of 0.76 beat LifeStance Health Group's score of 0.61 indicating that InnovAge is being referred to more favorably in the media.
InnovAge presently has a consensus target price of $6.50, indicating a potential upside of 46.40%. LifeStance Health Group has a consensus target price of $8.80, indicating a potential upside of 57.99%. Given LifeStance Health Group's stronger consensus rating and higher possible upside, analysts plainly believe LifeStance Health Group is more favorable than InnovAge.
InnovAge has higher earnings, but lower revenue than LifeStance Health Group. InnovAge is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.
Summary
LifeStance Health Group beats InnovAge on 12 of the 18 factors compared between the two stocks.
Get InnovAge News Delivered to You Automatically
Sign up to receive the latest news and ratings for INNV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INNV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InnovAge Competitors List
Related Companies and Tools
